Thus, in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumour phenotype, whereas in others, mainly ovarian, neuroblastomas, and colorectal cancers, SPARC may function as a tumour suppressor (Tai and Tang, 2008). Here, SPARC is linked to cancer.